Osteosarcoma is the predominant primary malignant bone tumor that poses a significant global health challenge. MicroRNAs (miRNAs) that regulate gene expression are associated with osteosarcoma pathogenesis. Thus, miRNAs are potential therapeutic targets for osteosarcoma. Nanoparticles, widely used for targeted drug delivery, facilitate miRNA-based osteosarcoma treatment. Numerous studies have focused on miRNA delivery using nanoparticles to inhibit the progress of osteosarcoma. Polymer-based, lipid-based, inorganic-based nanoparticles and extracellular vesicles were used to deliver miRNAs for the treatment of osteosarcoma. They can be modified to enhance drug loading and delivery capabilities. Also, miRNA delivery was combined with traditional therapies, for example chemotherapy, to treat osteosarcoma. Consequently, miRNA delivery offers promising therapeutic avenues for osteosarcoma, providing renewed hope for patients. This review emphasizes the studies utilizing nanoparticles for miRNA delivery in osteosarcoma treatment, then introduced and summarized the nanoparticles in detail. And it also discusses the prospects for clinical applications.

The clinical prevention, diagnosis, treatment, and drug development of Alzheimer's disease (AD) require urgent detection of novel targets and methods. Autophagy and microglia are significantly associated with the pathogenesis of early AD. This study indicated that microRNA-375-3p can inhibit autophagy by promoting mTOR phosphorylation in normal physiological conditions, while microRNA-375-3p promoted autophagy and enhanced neural repair by inhibiting the expression of presenilin 1 in early AD pathogenesis. Furthermore, co-treatment of rapamycin, and microRNA-375-3p can synergistically promote the autophagy and microglial activation in a neuroprotective manner, clear Aβ accumulation, repair nerve damage, and alleviate cognitive dysfunction and memory defects in APP/PS1 TG mice. This research revealed the impact and mechanism of miR375-3p on the early stage of AD through in vivo and in vitro experiments and provides new ideas and directions for the early treatment of AD.

Amyotrophic lateral syndrome (ALS) is a progressive degenerative disorder characterized by motor neuron death and axon degeneration. Mitochondrial dysfunction plays a key role in the pathogenesis of ALS, the mechanism of which remains poorly understood. The B-cell lymphoma-2 (Bcl-2) family of proteins that control and mediate mitochondrial function and apoptosis, including the pro-apoptotic members Bcl2-Associated X (Bax), are involved in ALS development. The death receptor 6 (DR6) regulates motor neuron death in ALS, and DR6 antibodies can prevent axon degeneration and motor neuron damage by blocking DR6. Previous studies demonstrated that PSAP localized to mitochondria and was required for DR6-induced apoptosis. In this study, SOD1G93A was transfected into the motor neuron cell line NSC-34 to serve as an ALS cell model in vitro. The data assessed the role of PSAP in SOD1G93A-induced apoptosis and demonstrated that the overexpression of SOD1G93A, but not wtSOD1, induced PARP cleavage, caspase-3 activation, cytochrome c release, and Bax translocation. PSAP, Bax, and Bak were necessary for SOD1G93A-induced apoptosis, as silencing PSAP inhibited SOD1G93A-mediated cell death that was dependent on Bax–Bak interaction.

Cell therapies for intervertebral disc degeneration (IDD) are intended to replace lost intervertebral disc (IVD) cells. The key to this treatment is to promote the migration of transplanted cells to the lesion site. The purpose of this study was to evaluate the repair effect of umbilical cord mesenchymal stem cells (UCMSCs) labeled with Fe₃O₄@polydopamine nanoparticles (Fe₃O₄@PDA NPs) on rat caudal vertebra disc degeneration. We characterized UCMSCs labeled with Fe₃O₄@PDA NPs, analyzed the effects of nanoparticles on UCMSCs and evaluated UCMSCs labeled with Fe₃O₄@PDA NPs to repair IDD in vivo. We found that UCMSC Fe₃O₄@PDA NPs could enhanced the migration of UCMSCs by up-regulating the expression of CXC chemokine receptor type 4 (CXCR4) without effecting UCMSC functionality and the Fe₃O₄@PDA NPs-labeled UCMSC group had better disc height, better tissue morphology performance and a higher number of transplanted cells and induced notably better regeneration of IVD, evidenced by the higher expression of aggrecan, type II collagen, and Sox-9 and lower expression of Mmp-13, Tnf-α and Il-1β at both mRNA and protein levels than the unlabeled group. We demonstrated systemic delivery of UCMSCs labeled with Fe₃O₄@PDA NPs could be an appropriate protocol for accelerating and optimizing clinically applicable UCMSC treatment for IDD.